Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Stevanato Group S.p.A.NYSE: STVN

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents falls 16.5% from a year ago

Cash & equivalents stood at €78.64M at the end of Q2 FY2026, down 16.5% from a year earlier and down 29.6% from the prior quarter. Over 3 fiscal years it compounded at -17.1% a year.

Context

  • Cash & equivalents amounted to 3.0% of total assets at the end of Q2 FY2026, down 1.0 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -16.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€78.64M-29.6% QoQ
Last fiscal yearDec 2025
€130.54M+32.8% YoY
Year agoJun 2025
€94.17M-16.5% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.5%——
1 year+32.8%——
3-year CAGR-17.1%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

EUR · from the balance sheet

Latest · FY2025
130.54M EUR
Year-over-year change
+32.8%
4-year CAGR
-24.9%

Cash & Equivalents vs competitors

How STVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -16.5% is the 8th highest of 11, against a peer median of +11.6%.
  • Cash & equivalents amounts to 3.0% of total assets for STVN, versus a peer median of 4.4%.
STVN Competitors
Cash & Equivalents for STVN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BTSGBrightSpring Health Services, Inc. Common StockSep 2026$717.84M USD+411.5%+86.5%11.5%
BLCOBausch + Lomb CorporationJun 2026$367M USD+34.9%+0.3%2.6%
AXSMAxsome Therapeutics, Inc.Jun 2026$319.85M USD+5.6%+17.2%42.0%
AVTRAvantor, Inc.Jun 2026$306.8M USD-31.7%-0.7%2.6%
TFXTeleflex IncorporatedJun 2026$300.16M USD+18.3%+10.4%4.4%
ATRAptarGroup, Inc.Jun 2026$190.4M USD+17.7%+41.6%3.7%
NUVLNuvalent, Inc.Mar 2026$159.73M USD+32.2%+2.7%12.0%
MASIMasimo CorporationApr 2026$124.6M USD-4.7%-9.1%7.6%
STVNStevanato Group S.p.A.Jun 2026€78.64M EUR-16.5%-17.1%3.0%
CHEChemed CorporationJun 2026$40.22M USD-83.9%+0.2%2.5%
MMSIMerit Medical Systems, Inc.Sep 2026$0 USD-100.0%+97.3%—
Peer median (excluding STVN) —+11.6%+6.6%4.4%

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents411.04M228.74M69.6M98.27M130.54M
Short-term Investments27.17M27.91M749K02.2M
Net Receivables278.42M369.48M522.48M529.87M542.17M
Inventory148.92M213.25M255.32M245.22M268.09M
Other Current Assets49K5.69M3.63M933K(8.6M)
Total Current Assets865.97M845.78M861.89M880.12M934.4M
Property, Plant & Equipment (Net)415.41M660.69M1.05B1.26B1.4B
Goodwill47.24M47.24M49.98M49.98M49.96M
Intangible Assets31.93M32.16M30.99M33.59M36.85M
Long-term Investments1.97M1.83M5.15M5.64M6M
Tax Assets55.88M69.21M76.25M95.34M103.86M
Other Non-current Assets447K2.8M577K08.6M
Total Non-current Assets552.87M813.92M1.21B1.45B1.61B
Total Assets1.42B1.66B2.07B2.33B2.54B
Account Payables164.79M239.18M277.82M231.02M263.19M
Short-term Debt37.17M64.63M135.6M106.84M121.69M
Tax Payables27.82M42.09M30.82M32.06M0
Deferred Revenue50.61M53.89M58.8M44.67M43.78M
Other Current Liabilities5.33M(3.73M)11.15M15.45M106.91M
Total Current Liabilities338.62M462.5M574.39M477.47M535.57M
Long-term Debt183.99M133.75M242.05M305.23M337.64M
Deferred Tax Liabilities19.11M20.95M9.62M12.56M13.29M
Deferred Revenue (Non-current)0039.42M44.05M98.76M
Other Non-current Liabilities17.9M31.93M60.35M73.32M62.07M
Total Non-current Liabilities238.56M201.29M364.54M446.96M521.38M
Total Liabilities577.18M663.79M938.93M924.43M1.06B
Common Stock21.7M21.7M21.7M22.23M22.22M
Retained Earnings0623.35M757.86M863.44M876.41M
Accumulated OCI686.06M(10.49M)(9.11M)(13.75M)54.95M
Other Stockholders Equity134.32M0000
Minority Interest(415K)(220K)115K46K37.98K
Total Equity841.66M995.91M1.13B1.4B1.49B
Total Debt244.29M218.37M396.59M428.97M470.7M
Net Debt(166.75M)(10.37M)326.99M330.7M340.16M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.